Public Profile

Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd., commonly referred to as Glenmark, is a prominent global player in the pharmaceutical industry, headquartered in India. Founded in 1977, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets. Glenmark focuses on the development and manufacturing of innovative generics, specialty pharmaceuticals, and over-the-counter products. With a diverse portfolio that includes formulations in therapeutic areas such as dermatology, oncology, and respiratory, Glenmark is recognised for its commitment to research and development. The company has achieved significant milestones, including numerous product approvals and a robust pipeline of new therapies. Glenmark's dedication to quality and innovation has positioned it as a trusted name in the pharmaceutical sector, making notable strides in both domestic and international markets.

DitchCarbon Score

How does Glenmark Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

61

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Glenmark Pharmaceuticals's score of 61 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.

96%

Let us know if this data was useful to you

Glenmark Pharmaceuticals's reported carbon emissions

In 2024, Glenmark Pharmaceuticals reported total greenhouse gas emissions of approximately 15240000 kg CO2e for Scope 1, 69632000 kg CO2e for Scope 2, and 171146000 kg CO2e for Scope 3 emissions. This represents a significant commitment to addressing climate change, as the company has set ambitious reduction targets. Glenmark aims to reduce its absolute Scope 1 and 2 emissions by 35% by FY2035, using FY2021 as the baseline year. Additionally, the company plans to decrease Scope 3 emissions from purchased goods and services, fuel and energy-related activities, downstream transportation and distribution, and investments by 28% per ton of pharmaceutical products within the same timeframe. In 2023, Glenmark's emissions were slightly lower, with Scope 1 at about 12703000 kg CO2e, Scope 2 at 64812000 kg CO2e, and Scope 3 at 175069000 kg CO2e. The company has consistently disclosed emissions across all three scopes, demonstrating transparency in its environmental impact. Glenmark's targets align with industry standards for climate action, aiming to keep global warming well below 2°C. The commitment to reducing emissions reflects a proactive approach to sustainability within the pharmaceutical sector, positioning Glenmark as a responsible corporate citizen in the fight against climate change.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20202021202220232024
Scope 1
11,713,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
74,231,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
3,277,000
000,000,000
000,000,000
000,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Glenmark Pharmaceuticals's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Glenmark Pharmaceuticals is in IN, which has a very high grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Glenmark Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Intas

IN
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Novo Nordisk A Slash S

DK
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Novartis

CH
Pharmaceutical Preparation Manufacturing
Updated about 15 hours ago

Mankind Pharma

IN
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Lupin

IN
Pharmaceutical Preparation Manufacturing
Updated 15 days ago

Alembic Pharmaceuticals

IN
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers